Digestive Diseases and Sciences

, Volume 42, Issue 8, pp 1734–1740 | Cite as

Changes in Gastrin and Serum Pepsinogens in Monitoring of Helicobacter pylori Response to Therapy

  • Maria Perez-Paramo
  • Agustin Albillos
  • Jose Luis Calleja
  • Clara Salas
  • Maria Del Carmen Marin
  • Maria Luisa Marcos
  • Guillermo Cacho
  • Pedro Escartin
  • Jose Ortiz-Berrocal
Article

Abstract

The aims of this study in 50 patients with H.pylori infection and duodenal ulcer were to examine theeffect of eradication therapy on the serum levels ofgastrin, pepsinogen I, and pepsinogen II and to investigate whether monitoring of the serumchanges in these peptides after treatment could predictpatient outcome. H. pylori status was assessed at entryand one and six months after therapy by culturing and microscopic analysis of the gastric mucosaand by [14C]urea breath test. Significantdecreases were observed in the serum levels of gastrin(–11.4 ± 3%), pepsinogen I (–28.9± 4%), and pepsinogen II (–40.4 ±3%) in the 45 patients whose infection was eradicated,but not in the patients without eradication. Serumvalues of these peptides were unchanged in an additionalgroup of 10 patients that only received omeprazol, none of whom had H. pylorieradicated. The best cutoff point of the percentage ofeach peptide to predict patient outcome was 10% forgastrin and pepsinogen I, and 15% for pepsinogen II. Apepsinogen II decrease >15% resulted in the best markerof H. pylori clearance, accurately identifying patientoutcome 86.6% of the time, whereas the diagnosticaccuracy of gastrin and pepsinogen I was 61.7% and76.6%, respectively. Significant correlations werefound between the bacterial load assessed by histologywith the serum concentrations of pepsinogen I and II andwith the urease activity as measured by the amount of 14CO2 excreted. Inconclusion, eradication of H. pylori infection isfollowed by a significant drop in serum levels ofgastrin, pepsinogen I, and pepsinogen II. Changes in thelatter are the most uniform and may be used as an indirect tool to predicttreatment outcome.

PYLORI GASTRIN PEPSINOGEN I PEPSINOGEN II DUODENAL ULCER [14C]UREA BREATH TEST 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI: Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. Gastroenterology 83:204–209, 1982Google Scholar
  2. 2.
    Marshall BJ, Armstrong JA, McGechies DB, Glancy RJ: Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust B 142:436–439, 1985Google Scholar
  3. 3.
    Morris A, Nicholson G: Infection of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82:192–199, 1987Google Scholar
  4. 4.
    Rauws EAJ, Tytgat GNJ: Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335:1233–1235, 1990Google Scholar
  5. 5.
    Wagner S, Haruma K, Gladziwa U, Gladziwa U, Soudah B, Gebel M, Bleck J, Schmidt, Manns M: Infection and serum pepsinogen A, pepsinogen C and gastrin in gastritis and peptic ulcer: Significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 89:1211–1218, 1994Google Scholar
  6. 6.
    Chittajallu RS, Dorrian CA, Ardill JES, et al: Effect of Helicobacter pylori infection on serum pepsinogen I and plasma gastrin in duodenal ulcer patients. Scand J Gastroenterol 27:20–24, 1992Google Scholar
  7. 7.
    Orderda G, Vaira D, Holton J, Ainley C, Alatare F, Boero M, Smith A, Ansaldi N: H. pylori in children with peptic ulcer and their families. Dig Dis Sci 36:572–576, 1991Google Scholar
  8. 8.
    Hunter FM, Correa P, Fontham E, Ruiz B, Sobhan M, Samloff M: Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis. Dig Dis Sci 38:2081–2086, 1993Google Scholar
  9. 9.
    Cave T, Cave DR: H. pylori stimulates pepsin secretion from isolated rabbit gastric gland. Scand J Gastroenterol 26(suppl 181):9–14, 1991Google Scholar
  10. 10.
    Samloff IM: Slow moving protease and the seven pepsinogens: Electrophoretic demonstration of the existence of eight proteolytic fractions in human gastric mucosa. Gastroenterology 47:659, 1969Google Scholar
  11. 11.
    Bayerdörferr E, Lehn N, Hatz R, Mannes GA, Oertel H, Sauerbruch T, Stolte M: Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology 102:1575–1582, 1992Google Scholar
  12. 12.
    Mulholland G, Ardill JE, Filmore D, Chittajalhu RS, Fullarton GM, McColl KEL: Helicobacter pylori related hypergastrinemia is the result of a selective increase in gastrin 17. Gut 34:757–761, 1993Google Scholar
  13. 13.
    Graham DY, Go Mf, Lew GM, Genta RM, Rethfeld JF: Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing. Scand J Gastroenterol 28:690–694, 1993Google Scholar
  14. 14.
    Kramling HJ, Endres G, Teichmann RK, Demmel T, Merkle R, Brendel W: Antigen-induced gastrin release: An immunological mechanism of gastric antral mucosa. Adv Exp Med Biol 216A:427–428, 1987Google Scholar
  15. 15.
    Kaneko H, Nakada K, Mitsuma T, Uchida K, Furusawa A, Maeda Y: Helicobacter pylori infection induces a decrease in immunoreactive-somatostatin concentrations of human stomach. Dig Dis Sci 37:409–416, 1992Google Scholar
  16. 16.
    Hui WM, Lam SK, Ho L, Lai CL, Lok ASF, Ng MMT, Lau WY, Branicki FJ: Effect of omeprazole on duodenal ulcer-associated antral gastritis and H. pylori. Dig Dis Sci 36:577–582, 1991Google Scholar
  17. 17.
    Louw JA, Falck V, van Rensburg C, Zak J, Adams G, Marks IN: Distribution of Helicobacter pylori colonization and associated gastric inflammatory changes: Differences between patients with duodenal and gastric ulcers. J Clin Pathol 46:754–756, 1993Google Scholar
  18. 18.
    Debongnie JC, Pauwels S, Raat A, Meeus Y, Haoot J, Mainguet P: Quantification of Helicobacter pylori infection in gastritis and ulcer disease using simple and rapid carbon-14-urea breath test. J Nucl Med 32(6):1192–1198, 1991Google Scholar
  19. 19.
    Ghelan AM, Hale S, Coleman H, Radziwonik H: Lack of in vitro activity of omeprazole against Campylobacter pylori. J Clin Pathol 43:171–173, 1990Google Scholar
  20. 20.
    Klein PD, Malaty HM, Martin RF, Graham KS, Genta RM, Graham DY: Noninvasive detection of Helicobacter pylori infection in clinical practice: The 13C urea breath test. Am J Gastroenterol 91:690–694, 1996Google Scholar
  21. 21.
    Hazell SL, Borody TJ, Gal A, Lee A: Campilobacter pylori gastritis. Detection of urease as a marker of bacterial colonization and gastritis. Am J Gastroenterol 82:292–296, 1987Google Scholar
  22. 22.
    Raskov H, Lanng C, Gaarslev K, Fisher-Hansen B, Hauch O: Screening for Campylobacter pyloridis in patients with upper dyspepsia and the relation to inflammation of the human gastric antrum. Scand J Gastroenterol 22:568–572, 1987Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Maria Perez-Paramo
  • Agustin Albillos
  • Jose Luis Calleja
  • Clara Salas
  • Maria Del Carmen Marin
  • Maria Luisa Marcos
  • Guillermo Cacho
  • Pedro Escartin
  • Jose Ortiz-Berrocal

There are no affiliations available

Personalised recommendations